or immunosuppression (Twentyman, 1992) . Multidrug resistance reversal agents may also affect ATP-dependent transporters in the liver. Cyclosporin A and its non-immunosuppressive derivative PSC 833 potently inhibit the bile salt export pump in the canalicular plasma membrane of hepatocytes (Bšhme et al, , 1994a (Bšhme et al, , 1994b Kadmon et al, 1993) . The discovery of new and efficient MDR1 P-gp inhibitors with fewer side-effects is an important objective for future cancer chemotherapy. Effective chemosensitizers should be drugs that interact with MDR1 P-gp with high affinity and selectivity, thereby precluding its ability to extrude the cytotoxic drugs. A multidrug resistance reversal potency at nanomolar concentrations has been described for the acridone carboxamide derivative GG918 (Hyafil et al, 1993) and, more recently, for the cyclopropyldibenzosuberane modulator LY335979 (Dantzig et al, 1996) . Such compounds may allow for an increased selectivity for inhibition of MDR1 P-gp-mediated membrane transport.
For studies on the selectivity of MDR1 P-gp inhibitors, the measurement of ATP-dependent transport by hepatocyte canalicular plasma membrane vesicles provides most useful approach (Bšhme et al, , 1994a . P-gps have been localized to the canalicular membrane of hepatocytes (Thiebaut et al, 1987; Kamimoto et al, 1989) . Additional ATP-dependent export pumps that have been identified in this hepatocyte membrane domain include the ATP-driven bile salt export pump (BSEP), which secretes bile salts such as taurocholate (TC) into bile (Gerloff et al, 1998) , and the ATP-dependent conjugate export pump encoded by the MRP2 (cMOAT) gene which transports glutathione, glucuronate and sulfate conjugates of various exogenous and Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918 endogenous lipophilic substances (reviewed by Keppler and Kšnig, 1997) .
In the present study we determined the selectivity of the MDR1 P-gp inhibitor GG918 with respect to these different ATP-dependent transport systems in the hepatocyte canalicular membrane. The potency of GG918 was investigated in plasma membrane vesicles from human and rat. The inhibition of photoaffinity labelling by [ 3 H]azidopine in the presence of GG918 was demonstrated with recombinant rat Mdr1b P-gp. Moreover, GG918 was a very selective inhibitor for the in vivo hepatobiliary excretion of the MDR1/Mdr1b P-gp substrate [ 3 H]daunorubicin, whereas the excretion of [ 3 H]taurocholate and N-[ 3 H]acetyl-leukotriene E 4 , which are substrates for the BSEP and MRP2, respectively, was not significantly affected. [14,15,19,20-3 H 4 ]leukotriene (LT)C 4 (6.4 TBq mmol Ð1 ) were purchased from Du Pont NEN, Bad Homburg, Germany. N-[ 3 H]Acetyl-LTE 4 (1.85 GBq mmol Ð1 ) was synthesized in our laboratory using a chemical N-acetylation procedure (Guhlmann et al, 1995) . N-(n-Pentyl)-[ 3 H]quinidinium was synthesized in our laboratory as described (MŸller et al, 1994a) . [ 14 C]Doxorubicin (211 GBq mmol Ð1 ), [ 3 H]azidopine (1.96 TBq mmol Ð1 ), and unlabelled LTC 4 were from Amersham Buchler, Braunschweig, Germany. GG918, formerly also designated GF120918, is an acridone carboxamide derivative (Hyafil et al, 1993) (Figure 1 ), was kindly provided by Dr F Hyafil from the GLAXO laboratories, Les Ulis, France. Ketamine was from Parke-Davis, Berlin, Germany. Xylazine was purchased from Bayer, Leverkusen, Germany. ATP, 5′-AMP, creatine phosphate potassium salt and unlabelled taurocholate were purchased from Sigma, Deisenhofen, Germany. Creatine kinase and reduced glutathione were obtained from Boehringer Mannheim, Mannheim, Germany. Percoll and NICK spin columns filled with Sephadex G-50 fine were from Pharmacia-LKB, freiburg, Germany. Glass microfibre filters (type GF/F, pore size ³ 0.7 µm) were purchased from Whatman International Ltd., Maidstone, UK. Nitrocellulose filters (0.2 µm pore size) were from Schleicher & Schuell, Dassel, Germany. Scintillation fluids (Filter Count and Ultima Gold) were from Canberra Packard, Warrenville, IL, USA. Membranes of the recombinant mdr1b-BVinfected Sf9-cells were produced in our laboratory and kindly provided by Dr K MittenbŸhler .
MATERIALS AND METHODS

Materials
Animals
Male Wistar rats (200Ð250 g) were from the Charles River Wiga, Sulzfeld, Germany. Animals were maintained on an Altromin Nr. 1320 diet with free access to food and water.
Human liver
Liver samples were obtained perioperatively from excised hepatic tissue from a patient suffering from primary hepatocellular carcinoma. Pathological tissue was removed, as estimated by macroscopic inspection, and only normal tumour-free liver tissue was further processed.
Preparation and characterization of canalicular membranes
Membrane fractions enriched in the hepatocyte canalicular membrane domain were prepared and characterized from rat and human liver as described (Meier and Boyer, 1990; Kadmon et al, 1993; Bšhme et al, 1994b) .
Measurement of ATP-dependent daunorubicin and doxorubicin transport into canalicular membrane vesicles
The [ 14 C]doxorubicin and [ 3 H]daunorubicin transport was measured by centrifugation of the vesicles through a gel matrix (BŸchler et al, 1994) . NICK spin columns (0.2 g Sephadex G-50/3.3 ml), rinsed with 250 mM sucrose, 10 mM Tris-HCl, pH 7.4, were centrifuged at 400 g for 4 min at 4°C. Membrane vesicles (30 µg protein) were incubated in the presence of 4 mM ATP, 10 mM magnesium chloride, 10 mM creatine phosphate, 100 µg ml Ð1 creatine kinase, and the labelled substrate in 250 mM sucrose and 10 mM Tris-HCl (pH 7.4) at 37°C. The final volume was 110 µl. The standard substrate concentration was 20 µM. At the indicated time points, 20 µl aliquots were taken and diluted in 80 µl ice-cold Tris buffer (250 mM sucrose, 10 mM Tris-HCl, pH 7.4) and immediately loaded on Sephadex G-50 columns. The columns were eluted with 100 µl ice-cold Tris buffer and centrifuged at 400 g for 4 min at 4°C. The membrane vesicle-containing effluent was collected in scintillation vials and counted for radioactivity. In control experiments ATP was replaced by 5′-AMP. Transport rates were calculated by subtracting the values in the presence of 5′-AMP from those in the presence of ATP.
Measurement of ATP-dependent N-pentyl-quinidinium transport into canalicular membrane vesicles
The transport of N-(n-pentyl)-[ 3 H]quinidinium was measured by the rapid filtration technique using glass microfibre filters (pore size ³ 0.7 µm) (MŸller et al, 1994a) . The filters were presoaked in Tris-buffered saline (pH 7.4). This filtration was performed at a pressure of 850 mbar. Membrane vesicles were incubated in the standard incubation mixture as described above for [ 3 H]daunorubicin. The concentration of N-pentyl-[ 3 H]quinidinium was 1 µM. Samples of 20 µl were taken at the indicated time-points and diluted in 950 µl of ice-cold Tris-buffered saline (pH 7.4). This solution was applied to the microfibre filters and immediately rinsed with 5 ml of ice-cold Tris-buffered saline (pH 7.4) containing 0.05% (v/v) Tween 20 and 5 ml of Tris-buffered saline (pH 7.4). Vesicle-associated radioactivity retained on the filters was assessed by liquid scintillation counting. in 250 mM sucrose, 10 mM Tris-HCl (pH 7.4) . Membrane vesicles (30 µg of protein) were incubated as described above for the MDR1 P-gp substrates. Aliquots (20 µl) were taken at the indicated time-points, diluted in 1 ml of ice-cold incubation buffer and applied to the nitrocellulose filters. The filters were rinsed with 5 ml washing buffer containing 1 mM unlabelled taurocholate, 250 mM sucrose, 10 mM Tris-HCl (pH 7.4) and 5 ml buffer consisting of 250 mM sucrose, 10 mM Tris-HCl (pH 7.4).
Measurement of ATP-dependent taurocholate transport into canalicular membrane vesicles
In control experiments ATP was replaced by 5′-AMP. Vesicleassociated radioactivity retained on the filters was assessed by liquid scintillation counting.
Measurements of ATP-dependent LTC 4 transport into canalicular membrane vesicles
[ 3 H]LTC 4 transport was determined as described recently (Keppler et al, 1998) . The rinsing buffer consisted of 250 mM sucrose and 10 mM Tris-HCl (pH 7.4). Reduced glutathione was added to the incubation at a final concentration of 5 mM to prevent binding of 
Photoaffinity labelling with [ 3 H]azidopine
Membrane vesicle suspensions (75Ð100 µg protein) were diluted in 250 mM sucrose, 10 mM Tris-HCl (pH 7.4) and incubated with [ 3 H]azidopine (74 kBq, 1.2 µM) at 25°C for 25 min in the presence of 0.5% fetal calf serum. The membrane solution was irradiated at 254 nm for 2 min on ice. For the competition studies, vesicle suspensions were pre-incubated with 10 µM or 40 µM of GG918 for 25 min at 25°C. The labelled membranes were pelleted by centrifugation for 30 min at 100 000 g at 4°C. The pellet was resuspended in Laemmli buffer (Laemmli, 1970) and subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (7.5% acrylamide gel). After electrophoresis the gels were cut into slices of 2 mm thickness and dissolved in 0.5 ml of the tissue solubilizer Biolute-S (Zinsser Analytic, Frankfurt, Germany). Radioactivity was measured in a liquid scintillation counter.
In vivo elimination of daunorubicin, taurocholate and N-acetyl-leukotriene E 4 into bile
Rats were anaesthetized by intraperitoneal injection of ketamine (80 mg kg Ð1 ) and xylazine (12 mg kg Ð1 ). The cannulation of the common bile duct and of the superior vena cava through the jugular vein was performed while rats were under general anaesthesia. The bile flow was allowed to reach a steady-state for 30 min and the experiment was started by intravenous injection of 2.2 mg kg Ð1 body weight (4.0 µmol kg Ð1 ) of GG918. ; 100 nmol kg Ð1 body weight) were injected as a bolus 10 min later. Bile was collected in 5-min fractions for 90 min, and the radioactivity in these samples was determined by diluting aliquots of bile in 100% methanol. Supernatants of the methanol extract were dissolved in 10 ml of scintillation fluid and counted for radioactivity. In the control group, GG918 was replaced by a corresponding volume of the vehicle (PEG 400/H 2 O 1:1; v/v; diluted as described above).
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RESULTS
Kinetic characterization of the inhibition by GG918 of transport of MDR1 and Mdr1b P-gp substrates in human and rat hepatocyte canalicular membrane vesicles
Initial experiments compared the inhibitory effect of GG918 on ATP-dependent transport in canalicular membranes isolated from human and rat liver . N-(n-Pentyl)-[ 3 H]quinidinium, a quinidinium compound with a permanently charged nitrogen atom, which served as a high affinity substrate for MDR1 P-gp-mediated transport (MŸller et al, 1994a . The IC 50 value for GG918 in human hepatocyte canalicular membranes was 70 nM at a N-(npentyl)-[ 3 H]quinidinium concentration of 1 µM (Figure 2) . The ATP-dependent N-(n-pentyl)-[ 3 H]quinidinium transport was reduced to 36% by 100 nM GG918. In rat hepatocyte canalicular membranes the half-maximal inhibition of N-pentyl-[ 3 H]quinidinium transport by GG918 was observed at a concentration of 8 nM (Figure 3) indicating a more potent inhibition of the rat liver transporter as compared to human MDR1 P-gp (Figure 2) . Concentrations of 100 nM and 10 nM GG918 suppressed ATPdependent transport of N-pentyl-[ 3 H]quinidinium by 98% and 42%, respectively (Figure 2) . [ 14 C]Doxorubicin transport, measured at a substrate concentration of 20 µM, was halfmaximally inhibited by 80n M GG918 (Figure 3 ). Transport of [ 3 H]daunorubicin into inside-out oriented vesicles from rat hepatocyte canalicular membranes was inhibited by GG918 in a competitive manner (Figure 4) . The kinetic constants for the ATP-dependent daunorubicin transport were determined by LineweaverÐBurk plots and yielded an apparent K m of 33 µM and a V max of 721 pmol mg Ð1 min Ð1 . The K i value for GG918 was 35 nM for [ 3 H]daunorubicin transport (Figure 4 ).
Photoaffinity labelling with [ 3 H]azidopine
Membranes of recombinant Mdr1b-expressing Sf9 insect cells were used to show the specific affinity of azidopine to P-gp in photoaffinity labelling experiments. Membrane vesicles of recombinant mdr1 b-BV-infected Sf9 cells were exposed to [ 3 H]azidopine and revealed one major band at 140 kDa after irradiation and consecutive separation by SDS-PAGE ( Figure 5 ). As shown by C219 anti-P-gp antibody detection of this membrane preparation the labelled protein co-migrated with recombinant Mdr1b. Photoaf finity labelling in the presence of 40 µM GG918 caused an 80% reduction of [ 3 H]azidopine incorporation into the Mdr1b protein. In these insect membranes we observed a very low unspecific binding of [ 3 H]azidopine. In contrast, in rat canalicular membranes several [ 3 H]azidopine-labelled proteins were detected (Figure 6 ). Only the incorporation of radioactivity in the 145 kDa protein, which corresponds to a C219 antibody-detectable P-gp, was decreased by preincubation with GG918 in a dose-dependent manner (Figure 6 ). The presence of 10 µM and 40 µM GG918 reduced the [ 3 H]azidopine labelling of rat P-gp by 38% and 78%, respectively. 
In vitro inhibition of three different ATP-dependent export pumps in hepatocyte canalicular membranes by GG918
In inside-out oriented vesicles of rat canalicular membranes [ 3 H]LTC 4 transport was not significantly inhibited at GG918 concentrations up to 20 µM. The ATP-dependent BSEP, determined with [ 3 H]taurocholate as substrate, was inhibited by 50% at a GG918 concentration of about 3 µM. The high selectivity of the inhibitor for Mdr1b P-gp was indicated by a half-maximal inhibition at about 20 nM GG918 at a [ 3 H]daunorubicin concentration of 20 µM (Figure 7 ). body weight) after 90 min was 9.7 ± 1.6% (n = 4; mean ± SD) in control experiments without GG918 (Figure 8 ). GG918 pretreatment 10 min before tracer injection reduced this biliary excretion of [ 3 H]daunorubicin to 29% of the control. The cumulative biliary elimination of this tracer after GG918 pretreatment was 2.8 ± 0.3% of the injected dose. In a single experiment (data not shown) the dose of the inhibitor was raised from 4 to 14 µmol kg Ð1 body weight. This resulted within the initial 30 min in a complete suppression of the [ 3 H]daunorubicin elimination into bile. After 90 min the cumulative secretion of [ 3 H]daunorubicin was reduced to 13% of control corresponding to a total recovery of 1.3% of the administered radioactivity after the high dose of GG918. In addition, [ 14 C]doxorubicin (175 pmol kg Ð1 body weight; 37 kBq kg Ð1 ) was injected to rats with or without GG918 (14 µmol kg Ð1 body weight; data not shown). The biliary recovery of [ 14 C]doxorubicin was 11.4% after 60 min in untreated animals. GG918 reduced the recovery to 3.0 ± 0.5% (n = 4; mean ± SD) of the injected dose corresponding to a suppression of the [ 14 C]doxorubicin elimination to 27%. N-Acetyl-LTE 4 is the major metabolite of endogenous cysteinyl leukotrienes in rat bile (Denzlinger et al, 1985) and a substrate for the ATP-dependent conjugate export pump MRP2 in the hepatocyte canalicular membrane (Ishikawa et al, 1990 ). N-[ 3 H]acetyl-LTE 4 was therefore chosen in our experiments as the substrate for this export pump. No significant inhibition of N-[ 3 H]acetyl-LTE 4 secretion was observed after administration of GG918 (4 µmol kg Ð1 ). The biliary recovery of intravenously administered N-[ 3 H]acetyl-LTE 4 (100 nmol kg Ð1 body weight) was 93 ± 4% (n = 4; mean ± SD) of the biliary secretion in animals without GG918. Moreover, the injection of GG918 (4 µmol kg Ð1 body weight) did not affect the biliary excretion of [ 3 H]taurocholate (2 nmol kg Ð1 body weight) as the major substrate of the BSEP (Figure 8 ). GG918 at 25°C for 25 min. The samples were photoaffinity labelled as described in Materials and methods and separated by SDS-PAGE using a 7.5% acrylamide gel. The peak at 145 kDa corresponds to the C219 antibody-detected Mdr P-gp. Arrows on the right of the 145 kDa peak indicate the decreased labelling of the 145 kDa protein by [ 3 H]azidopine in the presence of 10 µM GG918 and 40 µM GG918 
Effect of GG918 on the hepatobiliary excretion of substrates for different ATP-dependent export pumps in vivo
DISCUSSION
The ability to reverse one important type of multidrug resistance in cancer patients by inhibition of MDR1 P-gp-mediated drug transport by chemosensitizing agents is limited by the extent of toxic side-effects and by the selectivity of the MDR1 P-gp-inhibitor. Verapamil and cyclosporin A are well characterized examples of MDR1 P-gp-modulating compounds (Watanabe et al, 1995) . However, verapamil has cardiac side-effects and lowers the blood pressure (Pennock et al, 1991) , and the use of cyclosporin A is limited by its immunosuppressive action (Twentyman, 1992) and by its inhibition of ATP-dependent export pumps other than MDR1 P-gp (Bšhme et al, , 1994a (Bšhme et al, , 1994b Kadmon et al, 1993) . In the present study we have determined the potency of the acridone carboxamide derivative GG918 for inhibition of three different ATP-dependent export pumps in the hepatocyte canalicular membrane:
1. The rat mdr1b gene-encoded multidrug resistance export pump 2. The BSEP, encoded by the so called sister of P-glycoprotein (spgp; Gerloff et al, 1998) 3. The MRP2 (cMRP/cMOAT) gene-encoded conjugate export pump (Keppler and Kšnig 1997) .
Among these ATP-dependent transporters for daunorubicin, as substrate for Mdr1b P-gp (Kamimoto et al, 1989) , taurocholate as substrate for the BSEP (Adachi et al, 1991; MŸller et al, 1991; Nishida et al, 1991; Gerloff et al, 1998) , and LTC 4 as well as N-acetyl-LTE 4 , as substrates for Mrp2 (Ishikawa et al, 1990; Keppler and Kšnig, 1997) , the Mdr1b P-gp export pump exhibited the highest susceptibility to inhibition by GG918 in vitro and in vivo (Figures 7 and 8) . In comparison to the previously reported MDR1 P-gp inhibitors, except for the recently described modulator LY335979 (Dantzig et al, 1996) , inhibition of the ATPdependent transport of several structurally different MDR1 P-gp substrates was observed at a lower concentration of GG918, and half-maximal inhibition was detected between 8 nM and 80 nM (Figures 2, 3 and 7) . This was shown for daunorubicin and doxorubicin as well as for the more hydrophilic N-pentyl-quinidinium. The different IC 50 values for the substrate N-pentyl-[ 3 H]quinidinium in human (70 nM) and rat liver canalicular membranes (8 nM) may be due to the species difference of the MDR1 and Mdr1b transporters with an amino acid sequence identity of 81% (Brown et al, 1993) . Cyclosporin A is less specific as a MDR1 P-gp inhibitor and affects other ATP-dependent export pumps, particularly the ATP-dependent BSEP . In the rat, the inhibition of the latter pump by cyclosporin A induces intrahepatic cholestasis (Bšhme et al, 1994a (Bšhme et al, , 1994b . PSC 833, a non-immunosuppressive cyclosporin A derivative (Boesch et al, 1991 ) also inhibits several other ATP-dependent export pumps (Bšhme et al, , 1994a and is not as potent as GG918 with respect to inhibition of MDR1/Mdr1b P-gp (Figures 2Ð4). The inhibitory efficiency estimated by the K m /K i ratio was 942 for GG918 when daunorubicin was used as the substrate. This value is 14-fold higher than the ratio for PSC 833 and 70-fold higher than this ratio for cyclosporin A . GG918 does not seem to cause cytotoxicity in the concentrations required for modulation of multidrug resistance and unspecific toxic side-effects have not been observed at concentrations which were 100-fold above those necessary for specific MDR1 P-gp inhibition (Hyafil et al, 1993) .
Many modulators of the MDR1 P-gp-mediated multidrug resistance are lipophilic and heterocyclic compounds with a basic nitrogen atom at physiological pH (Ford et al, 1989; Pearce et al, 1989; Hait and Aftab, 1992) . The acridone carboxamide derivative GG918 exhibits these properties as well (Figure 1 ) and shows a high potency for inhibition of N-pentyl-quinidinium and daunorubicin transport (Figures 2Ð4) . The different IC 50 values of GG918 for three different ATP-dependent export pumps of the canalicular membrane offers the possibility to inhibit the MDR1 P-gp export pump at a concentration of GG918 at which the conjugate and bile salt export pumps are not or only little affected. Our studies in vitro are in line with our in vivo studies in the rat where GG918 at the dose of 2 mg kg Ð1 influenced only the Mdr1b P-gp-mediated excretion into bile (Figures 7 and 8) . The similar bile flow rates of control and GG918-treated animals indicate that the processes involved in bile formation are not affected by this dose of the inhibitor. A higher dose of GG918 (8 mg kg Ð1 ) caused a nearly complete suppression of the [ 3 H]daunorubicin secretion into bile during the initial 30 min after injection of GG918. This dose is in a range similar as the one which increased the survival time of tumour-bearing mice undergoing chemotherapy (Hyafil et al, 1993) .
In photoaffinity labelling studies with [ 3 H]azidopine we demonstrated an inhibition of the labelling by GG918 that is consistent with the high affinity of GG918 to Mdr1b P-gp in hepatocyte canalicular membranes (Figure 6 ). GG918 also competed with [ 3 H]azidopine for binding to the rat Mdr1b P-gp overexpressed in Sf9 cells ( Figure 5 ). The low level of non-specific labelling in membranes from Sf9 cells shows the suitability of such membranes for these experiments. On the other hand, hepatocyte canalicular membranes showed non-specific binding of [ 3 H]azidopine to several proteins that was not competed for by GG918 ( Figure 6 ). Our kinetic studies indicated a competitive inhibition of [ 3 H]daunorubicin transport by GG918 (Figure 4) . These results are compatible with the assumption that GG918 binds with high affinity to the substrate binding site of Mdr1b Pgp. The concentration of GG918 required for potent competition with [ 3 H]azidopine photoaffinity labelling was at least 100-fold higher than the concentration necessary for potent inhibition of substrate transport by Mdr1b P-gp. While it is not possible to compare the kinetic processes during photoaffinity labelling with the kinetics of ATP-dependent membrane transport, it should be noted that suppression of photoaffinity labelling usually requires much higher concentrations than inhibition of transport. This may be exemplified by the suppression of photoaffinity labelling by [ 3 H]LTC 4 with the potent transport inhibitor MK571 (Nicholson et al, 1992; Leier et al, 1994) , or by the competitive photoaffinity labelling of intestinal bile salt binding sites using 7, 7-azo-taurocholate (Lin et al, 1990) . Highly potent inhibition of MDR1/Mdr1b P-gp may cause an impaired detoxification of substances in non-malignant P-gpexpressing tissues. As shown for the mdr1a gene knock-out mice, a total loss in Mdr1a function may lead to an entry of toxic substances into normal tissues such as the brain (Schinkel et al, 1994) . Accordingly, potent inhibition of MDR1 P-gp in the bloodÐbrain barrier may be followed by an action of toxic and non-toxic compounds on the brain that is prevented under normal conditions by the function of MDR1 P-gp. Such inhibition may be desirable, however, not only during chemotherapy of brain tumours, but also during antibacterial chemotherapy with substances that are substrates for MDR1 P-gp in the bloodÐbrain barrier. The high potency and selectivity of a compound like GG918 for MDR1 P-gp not only offers a chance to reverse this type of multidrug resistance but also to study the physiological role of P-gp in several species.
